Skip to content
Screener

Repligen RGEN Total Equity

Total Equity at other companies

Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$52.69B+4.3%
Danaher logo
DanaherDHR
$52.58B+0.5%
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
$211.56M-29.6%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$6.85B+2.6%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$2.84B-15.3%
TEC
Bio-TechneTECH

Other financials

Income statement

See full
Revenue$204.1M+11.9%
Gross profit$110.0M+20.7%
Operating income$14.0M+0.6%
Net income$5.0M-66.3%
EPS (diluted)$0.09-65.4%

Balance sheet

See full
Cash & equivalents$606.8M-14.4%
Total debt$690.9M+354%
Total assets$3.0B+1.7%

Cash flow

See full
Operating cash flow$32.8M+14.5%
CapEx$5.3M-24.9%
Free cash flow$27.4M+27.5%

Valuation

See full
Market cap$8.95B+42.1%
Enterprise value$9.03B+57.3%
P/E215.5×
P/S11.6×+0.3×

Profitability

See full
Gross margin47.6%+0.9pp
Operating margin15.6%-11.0pp
Net margin17.3%-3.5pp
FCF margin22%+6.9pp

Returns & leverage

See full
Return on equity2%+1.6pp
Debt / equity0.3×+0.3×
Current ratio9.1×+0.5×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Repligen’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323773
Line itemJune 30, 2026December 31, 2025
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.01 par value; 80,000,000 shares authorized; 56,427,067 shares at June 30, 2026 and 56,325,429 shares at December 31, 2025 issued and outstanding564563
Additional paid-in capital1,661,6651,651,849
Accumulated other comprehensive loss(19,786)(2,531)
Retained earnings469,589456,248
Total stockholders’ equity2,112,0322,106,129
Total liabilities and stockholders’ equity$2,950,180$2,949,699

ITEM 1. Financial Statements

FAQ

What is Repligen's total equity?
Repligen (RGEN) reported total equity of $2.11B in Q2 2026.
How has Repligen's total equity changed year-over-year?
Repligen's total equity increased by 2.4% year-over-year, from $2.06B to $2.11B.
What is the long-term trend for Repligen's total equity?
Over 5 years (2020 to 2025), Repligen's total equity has grown at a 6.6% compound annual growth rate (CAGR), from $1.53B to $2.11B.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Repligen's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude